Thermo Fisher Scientific acquires viral vector manufacturing business from Novasep

Expanded global capacity addresses growing demand for cell and gene therapy

0
120
Thermo Fisher Scientific
Image: National Cancer Institute

Thermo Fisher Scientific (NYSE: TMO), the enterprise in serving science, and Groupe Novasep SAS (Novasep), a supplier of services and technologies for the life sciences industry, recently announced that Thermo Fisher has completed the acquisition of Henogen S.A., Novasep’s viral vector manufacturing business in Belgium for approximately EUR 725 million in cash (approximately Rs 6411 crore).

Novasep’s viral vector manufacturing business provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. With two locations in Seneffe and Gosselies, Belgium, Novasep’s viral vector business offers more than 7,000 square meters of state-of-the-art clinical and commercial manufacturing capacity. Founded more than 20 years ago, the business has approximately 400 employees with substantial operational and technical expertise in a broad range of viral vector classes and estimated 2020 revenue of EUR 80 million (or approximately $95 million).

“Novasep’s viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally,” said Michel Lagarde, executive vice president of Thermo Fisher. “The addition of their manufacturing capabilities in Europe complements our four development and manufacturing sites in North America. In addition, they bring an incredibly talented team with more than two decades of experience across a broad range of viral vectors. The combination will benefit our global customers seeking support and capacity in the region as well as European customers bringing new medicines to patients inside and outside of Europe.”

Michel Spagnol, president and chief executive officer of Novasep, said, “Thermo Fisher is an outstanding partner for our viral vector business and its future development. Our diverse customer base will benefit from the combination of our viral vector services capabilities with the scale and capabilities of Thermo Fisher. Our talented employees will bring deep expertise to an organization that shares our commitment to providing ground-breaking new medicines to patients.”

The business will be part of the Pharma Services business within the laboratory products and services segment.

Thermo Fisher Scientific is the world leader in serving science, with annual revenue exceeding $25 billion. Its mission is to enable its customers to make the world healthier, cleaner, and safer. Its global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience, and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon.

Novasep is a global provider of cost-effective and sustainable manufacturing solutions for life sciences molecules. Novasep’s unique offering includes process development services, purification equipment, and turnkey processes, contract manufacturing, and complex active molecule services for pharmaceutical, biopharmaceutical, fine chemical, food, and functional ingredients as well as fermentation and chemical commodities industries.

LEAVE A REPLY

Please enter your comment!
Please enter your name here